| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Cystic Fibrosis Group, Centre for Infectious Diseases, University of Edinburgh Medical School, The Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK
2 Department of Microbiology, Papworth Hospital NHS Trust, Papworth Everard, Cambridge CB3 8RE, UK
3 The Whitchurch Laboratory, Department of Microbiology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria 3800, Australia
Correspondence
Dervla Kenna
dkenna{at}staffmail.ed.ac.uk
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Individuals with cystic fibrosis (CF) are particularly susceptible to lung infection by a limited spectrum of microbial pathogens, of which P. aeruginosa is the most important cause of morbidity and mortality. Initial P. aeruginosa infection in CF is believed to derive from environmental sources and occurs early, in the infant or young child (Gibson et al., 2003). The non-mucoid colonial form of P. aeruginosa typical of early infection is relatively susceptible to antibiotics and can be eradicated if treated rapidly and aggressively (Burns et al., 2001). However, if treatment is delayed or ineffective, a chronic mucoid phenotype eventually emerges. The establishment of chronic infection with mucoid P. aeruginosa is a critical development, since pseudomonas alginate in association with bronchial mucin forms complex biofilms that in turn lead to antibiotic resistance, frustrated phagocytosis and a vicious cycle of neutrophil-mediated inflammation.
In the last decade, the emergence of highly transmissible strains of P. aeruginosa has presented yet another challenge to the CF community. There have been several well-documented outbreaks caused by ‘epidemic’ strains, which are typically multi-drug resistant (Cheng et al., 1996; McCallum et al., 2001; Armstrong et al., 2002). Some of these strains have unusual characteristics such as atypical colonial morphology and an enhanced ability to survive aerosolization and to infect extrapulmonary sites (Jones et al., 2003; Taylor et al., 1992; Panagea et al., 2005; Salunkhe et al., 2005; Chambers et al., 2005). The microbial factors responsible for enhanced transmissibility are unclear. However, it is clear that these strains pose a serious problem for cross-infection control and antimicrobial therapy.
The molecular mechanisms underlying the adaptation of P. aeruginosa to the CF lung are poorly understood, but undoubtedly complex. A recent longitudinal study by Smith et al. (2006) demonstrated the importance of mutation in the adaptation of P. aeruginosa to the CF lung, and the role that a hypermutation phenotype might play in bacterial pathogenesis in general. Hypermutable bacteria, or ‘hypermutators’, are bacteria that have an increased (up to 1000-fold) mutation rate. This phenomenon was initially identified in pathogenic Escherichia coli (Herman & Modrich, 1981), and occurs when defects in the bacterial DNA repair or error avoidance genes lead to a general increase in mutation frequency. Some of these secondary mutations may have a positive effect on bacterial survival, including advantageous properties such as antibiotic resistance and increased virulence. Recently, there has been much interest in the role of hypermutable bacteria in CF lung disease. A seminal study by Oliver et al. (2000) revealed that 37 % of CF patients chronically infected with P. aeruginosa were colonized by hypermutable strains; this contrasted with the absence of hypermutators in acute pseudomonas infections of non-CF patients. It has been suggested that the unique environment of the CF lung, with its variable nutrient supply, fluctuating inflammatory response and exposure to aggressive and prolonged antibiotic therapy, is highly susceptible to the establishment of a stable hypermutable phenotype (Oliver et al., 2000; Ciofu et al., 2005). Subsequently, other studies have shown that the mutator phenotype is relatively common in chronic P. aeruginosa infection in other lung disorders exhibiting a similar pathology to CF (Maciá et al., 2005). Hypermutable populations have also been identified in other major CF pathogens, namely Haemophilus influenzae and Staphylococcus aureus (Watson et al., 2004; Román et al., 2004; Prunier et al., 2003).
The association between antimicrobial resistance and hypermutability in chronic CF infections is well documented (Oliver et al., 2000, 2004; Maciá et al., 2004, 2005) and has important implications for antimicrobial therapy, in particular early treatment on first isolation of P. aeruginosa infection to prevent or delay chronic infection (Burns et al., 2001; Maciá et al., 2005). It is also clear that hypermutable P. aeruginosa have a propensity for survival in the chronically infected CF lung (Oliver et al., 2000). However, to our knowledge, the mutator phenotype has not been studied in other P. aeruginosa populations involved in CF lung disease. Thus in the present study, we assessed the prevalence of hypermutators within three different P. aeruginosa populations: (1) early clinical isolates from the CF lung, (2) environmental isolates that are considered to be the source of the majority of CF populations and (3) epidemic strains exhibiting multiple drug resistance and enhanced transmissibility. In P. aeruginosa the most commonly affected genes leading to hypermutabilty are those belonging to the mismatch repair system, in particular mutS (Oliver et al., 2000, 2002). Isolates found to be strongly hypermutable were investigated further to define the genotypic basis of their hypermutator phenotype.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). Clonality was excluded across all three groups by PFGE (Butler et al., 1995), with the exception of three patients whose primary infection involved an epidemic strain, and two of the environmental isolates. P. aeruginosa PAO1 and the hypermutable strain, P. aeruginosa J3295 (RH04 00 0003-2) were used as negative and positive controls, respectively. One hundred early isolates from 95 patients originated from respiratory samples from nine CF clinics in the UK and one clinic in Belgium; these were held in the Edinburgh CF Microbiology Laboratory and Strain Repository (ECFML) and had a non-mucoid phenotype, consistent with initial colonization. Isolates with a mucoid phenotype were excluded as this suggested established infection rather than early colonization. The panel of 15 epidemic strains comprised isolates from 13 separate outbreaks in CF clinics in the UK, Australia, Germany and the Republic of Ireland (Table 1). Twenty-three environmental strains were cultured from water, soil, or vegetable matter following enrichment in acetamide broth (Kelly et al., 1983; Curran et al., 2005) and overnight growth on Pseudomonas Isolation Agar (BD Biosciences) at 37 °C. Nine environmental isolates were kindly provided by Professor Peter Vandamme (Universiteit Gent, Belgium).
|
. Briefly, independent triplicate 20 ml Mueller–Hinton broth (MHB) cultures of each strain (3–5 colonies) were grown overnight in an orbital incubator at 37 °C. Cells were pelleted, resuspended in 1 ml MHB and serial 10-fold dilutions were prepared in sterile saline. Samples (100 µl) of the neat, 10–1 and 10–2 dilutions were plated on Mueller–Hinton agar (MHA) with 300 µg rifampicin ml–1, and 100 µl of the 10–6, 10–7 and 10–8 dilutions were plated on to MHA without antibiotics. After 36 h incubation, colonies were counted and 10 colonies of each morphotype were streaked on to new antibiotic plates to assess mutant stability. The mean number of mutants was calculated for each strain. For any strains displaying mutation jackpot (that is, the chance appearance of a large number of mutants in one of the triplicate experiments), the triplicate experiment was repeated. Strains were divided into four categories based on mutation frequency. These were: normomutable (based on a mutation frequency, f, close to the modal point of the distribution of mutation frequencies, in this case between 7x10–9 and 2x10–7), weak mutators (strains with a mutation frequency of 2x10–7 >f <1x10–6) and strong mutators (f 
1x10–6; approximately 20-fold greater than that of PAO1). Finally strains with f <7x10–9 were considered to be hypomutable. To monitor reproducibility, PAO1 and a known hypermutator, strain J3295 (RH04 00 0003-2), were tested in triplicate in each experiment.
PCR and sequencing.
Ten primer pairs were designed to span the 2.5 kb mutS gene, based on the sequence from the PAO1 genome sequence database (http://www.tigr.org/) (Table 2). For DNA extraction, a boiled preparation was made for each strain using the following method. One or two colonies were taken from overnight growth on nutrient agar (Columbia agar, Oxoid) and mixed with 20 µl lysis buffer (0.25 %, w/v, SDS in distilled water, 0.05 M NaOH, 92.8 ml MilliQ water). After incubation for 15 min at 95 °C, the sample was pulsed in a centrifuge, 180 µl MilliQ water was added and a final centrifugation was performed for 5 min at 16 110 g. Each 25 µl PCR reaction contained the following reagents: approximately 20 ng DNA, 250 µM of each deoxynucleoside triphosphate, 1.5 mM MgCl2 (Qiagen), 1x PCR buffer (Qiagen), 20 pmol of each primer (Invitrogen), 1.25 U Hot starTaq polymerase (Qiagen) and sterile distilled water. DNA was amplified in a TC-312 thermal cycler (Techne). PCR conditions were as follows: 1 cycle of 95 °C for 15 min, followed by 30 cycles of 95 °C for 1 min, 1 min at the appropriate annealing temperature for the mutS primer pair used (Table 2) and 72 °C for 1 min, with a final extension step of 72 °C for 10 min. Samples (10 µl) of PCR product were run alongside a 1 kb Plus DNA ladder (Invitrogen) on a 1.2 % pre-cast E-gel (Invitrogen). PAO1 was used as a positive control and the negative control consisted of PCR reaction mix without DNA. PCR products were purified using the QIAquick PCR purification kit (Qiagen) and sequenced using both forward and reverse primers. Sequencing conditions were as follows: 1 cycle of 95 °C for 1 min, 25 cycles of 95 °C for 30 s, 45 °C for 15 s, and 60 °C for 4 min. The sequencing mixture consisted of 4 µl ABI PRISM BigDye terminator v3.1 cycle sequencing mix (Applied Biosystems), 40 pmol primer (the same primers as had been used for PCR) and 1–2 µl DNA, depending on the concentration of DNA. The mixture was made up to 20 µl with sterile distilled water. Vector NTI 8 suite (InforMax) was used to analyse DNA sequences. Sequences were compared to the published PAO1 genome sequence (http://www.tigr.org/).
|
. |
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
shows the distribution of mutation frequencies for the 100 early or first isolates from CF infants and children. Resulting mutation frequencies revealed that 85/100 (85 %) were normomutable; 5/100 (5 %) were hypomutable, 5/100 (5 %) were weak mutators and 5/100 (5 %) were strong hypermutators (Figs 1a and 2; Table 3). Of the 32 environmental isolates, 1/32 (3 %) was hypomutable and 29/32 (91 %) were normomutable. The remaining 2/32 (6 %) were weak mutators with mutation frequencies of 7.2x10–7 and 4.3x10–7, respectively (Figs 1b and 2). Clonality of these two isolates was excluded using PFGE. Of the 15 epidemic strains (Table 1), 7/15 (47 %) were hypomutable, 6/15 (40 %) were normomutable and 2/15 (13 %) were strongly hypermutable (Figs 1c and 2; Table 3). In view of the clinical importance of these epidemic strains, it was decided they should be looked at in greater depth in this study. Five strains from individual patients infected with the Manchester, Liverpool, Bristol and Dublin group 3 epidemic strains (Table 1) were screened with rifampicin. The results revealed some variation in the mutation frequencies between the same epidemic strain from different patients. Intriguingly, two of the three isolates whose hypermutator status differed from those in the cluster were mucoid variants, suggesting this may be important (Table 4). The Bristol epidemic strain, for example, was hypermutable in four out of five patients, but normomutable in the fifth (the mucoid isolate). Interestingly, one of the Manchester isolates had an unusually high mutation rate (3.5x10–2) with respect to the other isolates in this clonal group.
|
|
|
|
). Strain C4649 had a 4 bp insertion after the threonine at amino acid 398, leading to a frameshift, and thus altering the structure of the MutS protein. Strain E2889 had a single point mutation leading to a change in amino acid 636 from glycine to aspartic acid. This change is in domain V of the MutS protein, which has the important function of ATPase activity (Obmolova et al., 2000; Oliver et al., 2002).
Of the two epidemic strains found to be hypermutable, mutS screening showed that only one of these, strain E1457, had non-synonymous mutations in mutS. Two mutS mutations (A545T and Z693G) were found in this strain (Table 3). As far as we are aware, these sequence changes have not been reported previously; however, it seems plausible that one or other is responsible for the elevated mutation frequency since both are part of domain V of the MutS protein, which is involved in ATPase activity (Obmolova et al., 2000; Oliver et al., 2002).
PCR amplification of additional mismatch repair and error prevention genes
Early isolates C4662, C3182 and C4488, and epidemic strain E1284, had elevated mutation frequencies that could not be explained by mutS mutations. These isolates underwent mutL, mutL, uvrD, mutY, mutM, mutD and mutT PCR amplification. The resulting PCR products were the same size as those of the positive control, strain PAO1.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
, 2004; Ciofu et al., 2005; Maciá et al., 2004, 2005). However, it is not clear at what stage of infection the hypermutable phenotype emerges. In addition, the possibility that hypermutability might be responsible for the occurrence of epidemic P. aeruginosa has not, to our knowledge, been investigated. To address these issues, this study investigated the prevalence of hypermutators in three P. aeruginosa populations. Our hypothesis was that hypermutability would be rare in early and in environmental P. aeruginosa but could explain the phenomenon of epidemic strains. The resulting distribution of mutation frequencies revealed that, rather than isolates being broadly categorized as non-mutators and mutators, there were in fact a number of isolates that were weak mutators, and at the other end of the scale some that exhibited a lower than average mutation rate. This distribution led us to categorize isolates as hypomutable, normomutable, hypermutable or weak mutators, as had been done in a recent study by Baquero et al. (2004).
It was surprising to find that 10 % of early isolates were either strong or weak mutators, particularly since the emergence of hypermutators in the CF lung is believed to be uniquely associated with chronic infection (that is, with fluctuating inflammatory responses and prolonged antibiotic therapy) (Oliver et al., 2000; Maciá et al., 2005; Ciofu et al., 2005). To our knowledge, the effect of weak mutators in P. aeruginosa infection in CF has not been examined. It has been suggested, however, that in high-density populations of E. coli, advantageous mutations will tend to appear in weak mutators, and that these may sometimes prevent the fixation of strong mutators (Chao & Cox, 1983; Baquero et al., 2004).
The higher than predicted number of mutators in early infection suggested that the environment of the CF lung might not be the only factor influencing hypermutability in P. aeruginosa, and that at least some of these isolates might be hypermutable prior to infection of CF patients. Alternatively, although we restricted our study to non-mucoid P. aeruginosa, in some cases infection may already have existed for some time. Because it is widely believed that the source of most P. aeruginosa infection in CF is environmental we screened a panel of 32 environmental isolates for hypermutability. Interestingly, 2/32 (6 %) were weak mutators, with one of these being a borderline strong mutator. To our knowledge, hypermutators have not been reported previously for environmental P. aeruginosa. It is noteworthy that, as might be expected for both environmental and early populations, the percentage of weak mutators is similar, at 5 % and 6 %, respectively. In addition, these results do indeed suggest that, although the CF lung clearly plays an important role in the selection of hypermutable P. aeruginosa, the existence of weak mutators amongst environmental organisms should not be underestimated.
The relatively high number of strong and weak mutators in early CF infection, and to a lesser extent amongst environmental isolates, contrasts strikingly with numbers found in other P. aeruginosa populations. For example, results from a study by Gutiérrez et al. (2004) supported those of Oliver et al. (2000), in finding a very low proportion of P. aeruginosa hypermutators amongst intensive care patients infected with this organism. It is not clear why there is such a difference in the mutation frequencies between these studies but it seems plausible that the acute cases of P. aeruginosa, presumably derived from the nosocomial environment, may be under a different selective pressure than early and environmental isolates.
Results from the current study reinforce the importance of early and aggressive antimicrobial therapy as advocated by others (Burns et al., 2001; Oliver et al., 2004; Maciá et al., 2005). Oliver et al. (2004) addressed this problem with regard to chronic P. aeruginosa infection. They concluded that combinations of antipseudomonal agents should be used to minimize the selection for hypermutable antibiotic-resistant mutants. A further informative study supports the relevance of combined therapy for P. aeruginosa infection. Maciá et al. (2006) investigated mice infected with hypermutable P. aeruginosa and showed that resistance could be suppressed by appropriate therapy with more than one antibiotic.
Epidemic strains of P. aeruginosa are a relatively recent concern for CF patients. There have been several well-documented studies on transmissible strains, revealing in some cases a capacity for increased antimicrobial resistance, increased transmissibility factors and superinfection of existing P. aeruginosa infections (Jones et al., 2001, 2003; Panagea et al., 2005; McCallum et al., 2001). It seemed plausible that the characteristics favouring the survival and spread of these atypical transmissible P. aeruginosa isolates could be explained by the phenomenon of hypermutability. However, in our study the majority of epidemic strains studied were either hypo- or normomutable (47 % and 40 %, respectively). Only 2/15 (13 %) were strong mutators, suggesting that the phenomenon of epidemic strains cannot easily be explained by hypermutability. On closer examination, however, the situation proved to be complex. For example, strain E2331 from a patient whose first P. aeruginosa infection was with the Liverpool epidemic strain (LES) (Cheng et al., 1996; McCallum et al., 2001; Al-Aloul et al., 2005; Salunkhe et al., 2005) had a mutation frequency of 7.2x10–7, indicating that this strain was a weak mutator. This contrasted with a mutation frequency of 3.9x10–9 for strain H129 (derived from a different patient, and one of the first known examples of LES; Table 1). mutS sequencing of E2331 (Table 3) revealed a point mutation (A187S), which had coincidentally been found by Hogardt et al. (2006), using complementation studies, to be a cause of hypermutability. The consequences of this result are twofold. First, it demonstrates that even weak mutators (as defined by phenotypic screening) can exhibit mutS mutations, thus raising the question of what defines a mutator. This issue has been discussed in depth in a recent review of mutator phenotypes by Hall & Henderson-Begg (2006). Although initially this study aimed to declare any strain with a mutation frequency >20 times that of PAO1 (estimated by Oliver et al., 2000 to be approximately 4x10–7) to be a hypermutator, the number of resistant PAO1 colonies on the rifampicin plates was found to be sufficiently variable so as to make comparison of mutation frequencies between individual experiments unfeasible. It was therefore decided that a standard value (1x10–6) be used. As a result of setting a high threshold, it is clear that the number of hypermutators in this study may have been underestimated, a fact that has been highlighted by strain E2331. This result suggests that, in this study at least, weak mutators should also be considered to be potential hypermutators.
The second implication of the mutation frequency deviation between the two LES isolates is that it demonstrates the considerable intra-clonal variation exhibited by such strains, a characteristic elegantly demonstrated in a study by Salunkhe et al. (2005), who compared transcriptome profiles of two clones of LES from related patients. The fluctuation in mutation frequencies found in this study prompted a more in-depth analysis of these isolates. Screening of strains from individual patients infected with the Liverpool, Manchester, Bristol and Dublin group 3 epidemic strains revealed some interesting results, in particular a possible connection between mucoidy and mutation frequency within a clonal group. In addition, one of the Manchester epidemic strains had an unusually high mutation frequency compared to the other strains in this cluster. The variation in mutation frequencies does not appear to correlate with the stage of the outbreak, although this is difficult to prove without patient contact tracing. Rather, these results suggest that perhaps hypermutabilty in some of these epidemic strains is transient and is influenced by the state of an individual patient’s lungs, by antibiotic treatment at the time, or by the complex interplay between the microbial population in the CF lung, as has been suggested to occur in other bacterial populations (Rosche & Foster, 1999; Blazquez, 2003). It would be interesting to look in more detail at some of these isolates to establish whether transient mutation really is responsible for these differences and to establish what, if any, connection there might be between mucoidy and mutation rate.
Interestingly, mutS mutations that might explain the raised mutation frequency were found in only three of the seven strongly hypermutable strains found in this study, and even these would need to be confirmed by complementation studies. This result suggests that, in P. aeruginosa at least, genes other than mutS are a more common cause of hypermutability than previously thought. Oliver et al. (2002) found that after mutS, mutL and uvrD are the next most common genes to be disrupted in mutator strains. In our study, whole-gene amplification of these, as well as the other mismatch repair and error prevention genes mutY, mutM, mutD and mutT, did not reveal any significant deletions. It seems likely therefore that a point mutation in one of these genes is responsible for the hypermutable phenotype of the other four strains in this study.
In conclusion, this study has revealed a higher than predicted level of both strong and weak mutators in early P. aeruginosa infection in CF. These results strengthen the argument for an early and aggressive approach to antimicrobial therapy. The existence of a comparable number of weak mutators in a small environmental population of P. aeruginosa suggests that the CF lung is not the only influential factor in the occurrence of mutators. In addition, phenotypic screening of a group of epidemic strains has revealed that although hypermutability exists, other, as-yet-unidentified, factors are likely to play a more important role in the success of these strains. Lastly, mutS sequencing of the strong hypermutators only found non-synonymous mutations in three of seven strains, suggesting that genes other than mutS are a more common cause of elevated mutation rates in P. aeruginosa than previously thought.
|
ACKNOWLEDGEMENTS |
|---|
Edited by: P. Cornelis
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Armstrong, D. S., Nixon, G. M., Carzino, R., Bigham, A., Carlin, J. B., Robins-Browne, R. M. & Grimwood, K. (2002). Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 166, 983–987.
Armstrong, D., Bell, S., Robinson, M., Bye, P., Rose, B., Harbour, C., Lee, C., Service, H., Nissen, M. & other authors (2003). Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin Microbiol 41, 2266–2267.
Baquero, M.-R., Nilsson, A. I., del Carmen Turrientes, M., Sandvang, D., Galán, J. C., Martínez, J. L., Frimodt-Møller, N., Baquero, F. & Andersson, D. I. (2004). Polymorphic mutation frequencies in Escherichia coli: emergence of weak mutators in clinical isolates. J Bacteriol 186, 5538–5542.
Blazquez, J. (2003). Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 37, 1201–1209.[CrossRef][Medline]
Burns, J. L., Gibson, R. L., McNamara, S., Yim, D., Emerson, J., Rosenfeld, M., Hiatt, P., McCoy, K., Castile, R. & other authors (2001). Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 183, 444–452.[CrossRef][Medline]
Butler, S. L., Doherty, C. J., Hughes, J. E., Nelson, J. W. & Govan, J. R. W. (1995). Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?. J Clin Microbiol 33, 1001–1004.[Abstract]
Chambers, D., Scott, F., Bangur, R., Davies, R., Lim, A., Walters, S., Smith, G., Pitt, T., Stableforth, D. & Honeybourne, D. (2005). Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis. Eur Respir J 26, 651–656.
Chao, L. & Cox, E. C. (1983). Competition between high and low mutating strains of Escherichia coli.. Evolution 37, 125–134.[CrossRef]
Cheng, K., Smyth, R. L., Govan, J. R. W., Doherty, C., Winstanley, C., Denning, N., Heaf, D. P., van Saene, H. & Hart, C. A. (1996). Spread of a β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 348, 639–642.[CrossRef][Medline]
Ciofu, O., Riis, B., Pressler, T., Poulsen, H. E. & Hoiby, N. (2005). Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 49, 2276–2282.
Curran, B., Morgan, J. A. W., Honeybourne, D. & Dowson, C. G. (2005). Commercial mushrooms and bean sprouts are a source of Pseudomonas aeruginosa.. J Clin Microbiol 43, 5830–5831.
Edenborough, F. P., Stone, H. R., Kelly, S. J., Zadik, P., Doherty, C. J. & Govan, J. R. W. (2004). Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation. J Cyst Fibros 3, 37–44.[Medline]
Gibson, R. L., Burns, J. L. & Ramsey, B. W. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168, 918–951.
Goldberg, J. B. (2000). Pseudomonas: global bacteria. Trends Microbiol 8, 55–57.[CrossRef][Medline]
Gutiérrez, O., Juan, C., Pérez, J. L. & Oliver, A. (2004). Lack of association between hypermutation and antibiotic resistance development in Pseudomonas aeruginosa isolates from intensive care unit patients. Antimicrob Agents Chemother 48, 3573–3575.
Hall, L. M. C. & Henderson-Begg, S. K. (2006). Hypermutable bacteria isolated from humans – a critical analysis. Microbiology 152, 2505–2514.
Herman, G. E. & Modrich, P. (1981). Escherichia coli K12 clones that overproduce dam methylase are hypermutable. J Bacteriol 145, 644–646.
Hogardt, M., Schubert, S., Adler, K., Götzfried, M. & Heesemann, J. (2006). Sequence variability and functional analysis of MutS of hypermutable Pseudomonas aeruginosa cystic fibrosis isolates. Int J Med Microbiol 296, 313–320.[CrossRef][Medline]
Jones, A. M., Govan, J. R. W., Doherty, C. J., Dodd, M. E., Isalska, B. J., Stanbridge, N. & Webb, A. K. (2001). Spread of a multi-resistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet 358, 557–558.[CrossRef][Medline]
Jones, A. M., Govan, J. R. W., Doherty, C. J., Dodd, M. E., Isalska, B. J., Stanbridge, N. & Webb, A. K. (2003). Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross-infection outbreak. Thorax 58, 525–527.
Kelly, N. M., Falkiner, F. R. & Keane, C. T. (1983). Acetamide broth for isolation of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 17, 159
Maciá, M. D., Borrell, N., Pérez, J. L. & Oliver, A. (2004). Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa with the Etest and disk diffusion. Antimicrob Agents Chemother 48, 2665–2672.
Maciá, M. D., Blanquer, D., Togores, B., Sauleda, J., Pérez, J. L. & Oliver, A. (2005). Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49, 3382–3386.
Maciá, M. D., Borrell, N., Segura, M., Gómez, C., Pérez, J. L. & Oliver, A. (2006). Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 50, 975–983.
McCallum, S. J., Corkhill, J., Gallagher, M., Ledson, M. J., Hart, C. A. & Walshaw, M. J. (2001). Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P. aeruginosa. Lancet 358, 558–560.[CrossRef][Medline]
Obmolova, G., Ban, C., Hsieh, P. & Yang, W. (2000). Crystal structure of mismatch repair protein MutS and its complex with a substrate DNA. Nature 407, 703–710.[CrossRef][Medline]
Oliver, A., Canton, R., Campo, P., Baquero, F. & Blazquez, J. (2000). High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288, 1251–1253.
Oliver, A., Baquero, F. & Blázquez, J. (2002). The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterisation of naturally occurring mutants. Mol Microbiol 43, 1641–1650.[CrossRef][Medline]
Oliver, A., Levin, B. R., Juan, C., Baquero, F. & Blazquez, J. (2004). Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother 48, 4226–4233.
Panagea, S., Winstanley, C., Walshaw, M. J., Ledson, M. J. & Hart, C. A. (2005). Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and a study of its survival on dry surfaces. J Hosp Infect 59, 102–107.[CrossRef][Medline]
Prunier, A. L., Malbruny, B., Laurans, M., Brouard, J., Duhamel, J. F. & Leclercq, R. (2003). High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187, 1709–1716.[CrossRef][Medline]
Román, F., Canton, R., Perez-Vazquez, M., Baquero, F. & Campos, J. (2004). Dynamics of long-term colonisation of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol 42, 1450–1459.
Römling, U., Wingender, J., Müller, H. & Tümmler, B. (1994). A major cystic fibrosis clone common to patients and aquatic habitats. Appl Environ Microbiol 60, 1734–1738.
Rosche, W. A. & Foster, P. L. (1999). The role of transient hypermutators in adaptive mutation in Escherichia coli. Proc Natl Acad Sci U S A 96, 6862–6867.
Salunkhe, P., Smart, C. H., Morgan, J. A., Panagea, S., Walshaw, M. J., Hart, C. A., Geffers, R., Tummler, B. & Winstanley, C. (2005). A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol 187, 4908–4920.
Scott, F. W. & Pitt, T. L. (2004). Identification and characterisation of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 53, 609–615.
Smith, E. E., Buckley, D. G., Wu, Z., Saeniphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P. & other authors (2006). Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A 103, 8487–8492.
Spilker, T., Coeyne, T., Vandamme, P. & LiPuma, J. J. (2004). PCR-based assay for the differentiation of Pseudomonas aeruginosa from other species of Pseudomonas recovered from cystic fibrosis patients. J Clin Microbiol 42, 2074–2079.
Taylor, R. F., Morgan, D. W., Nicholson, P. S., Mackay, I. S., Hodson, M. E. & Pitt, T. L. (1992). Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis. Thorax 47, 426–428.
Watson, M. E., Jr, Burns, J. L. & Smith, A. L. (2004). Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150, 2947–2958.
Received 11 December 2006;
revised 12 February 2007;
accepted 16 February 2007.
This article has been cited by other articles:
|
|
 |
|
  L. F. Mandsberg, O. Ciofu, N. Kirkby, L. E. Christiansen, H. E. Poulsen, and N. Hoiby Antibiotic Resistance in Pseudomonas aeruginosa Strains with Increased Mutation Frequency Due to Inactivation of the DNA Oxidative Repair System Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2483 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Foweraker Recent advances in the microbiology of respiratory tract infection in cystic fibrosis Br. Med. Bull., March 1, 2009; 89(1): 93 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mena, E. E. Smith, J. L. Burns, D. P. Speert, S. M. Moskowitz, J. L. Perez, and A. Oliver Genetic Adaptation of Pseudomonas aeruginosa to the Airways of Cystic Fibrosis Patients Is Catalyzed by Hypermutation J. Bacteriol., December 15, 2008; 190(24): 7910 - 7917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Wiegand, A. K. Marr, E. B. M. Breidenstein, K. N. Schurek, P. Taylor, and R. E. W. Hancock Mutator Genes Giving Rise to Decreased Antibiotic Susceptibility in Pseudomonas aeruginosa Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3810 - 3813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Kirov, J. S. Webb, C. Y. O'May, D. W. Reid, J. K. K. Woo, S. A. Rice, and S. Kjelleberg Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis Microbiology, October 1, 2007; 153(10): 3264 - 3274. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
